TY - JOUR
T1 - Lung tumor suppressor GPRC5A binds EGFR and restrains its effector signaling
AU - Zhong, Shuangshuang
AU - Yin, Huijing
AU - Liao, Yueling
AU - Yao, Feng
AU - Li, Qi
AU - Zhang, Jie
AU - Jiao, Huike
AU - Zhao, Yongxu
AU - Xu, Dongliang
AU - Liu, Shuli
AU - Song, Hongyong
AU - Gao, Yong
AU - Liu, Jingyi
AU - Ma, Lina
AU - Pang, Zhi
AU - Yang, Ruixu
AU - Ding, Chengyi
AU - Sun, Beibei
AU - Lin, Xiaofeng
AU - Ye, Xiaofeng
AU - Guo, Wenzheng
AU - Han, Baohui
AU - Zhou, Binhua P.
AU - Chin, Y. Eugene
AU - Deng, Jiong
N1 - Publisher Copyright:
© 2015 AACR.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - GPRC5A is a G-protein-coupled receptor expressed in lung tissue but repressed in most human lung cancers. Studies in Gprc5a-/- mice have established its role as a tumor-suppressor function in this setting, but the basis for its role has been obscure. Here, we report that GPRC5A functions as a negative modulator of EGFR signaling. Mouse tracheal epithelial cells (MTEC) from Gprc5a-/- mice exhibited a relative increase in EGFR and downstream STAT3 signaling, whereas GPRC5A expression inhibited EGFR and STAT3 signaling. GPRC5A physically interacted with EGFR through its transmembrane domain, which was required for its EGFR inhibitory activity. Gprc5a-/- MTEC were much more susceptible to EGFR inhibitors than wild-type MTEC, suggesting their dependence on EGFR signaling for proliferation and survival. Dysregulated EGFR and STAT3 were identified in the normal epithelia of small and terminal bronchioles as well as tumors of Gprc5a-/- mouse lungs. Moreover, in these lungs EGFR inhibitor treatment inhibited EGFR and STAT3 activation along with cell proliferation. Finally, overexpression of ectopic GPRC5A in human non-small cell lung carcinoma cells inhibited both EGF-induced and constitutively activated EGFR signaling. Taken together, our results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis. Cancer Res; 75(9); 1801-14.
AB - GPRC5A is a G-protein-coupled receptor expressed in lung tissue but repressed in most human lung cancers. Studies in Gprc5a-/- mice have established its role as a tumor-suppressor function in this setting, but the basis for its role has been obscure. Here, we report that GPRC5A functions as a negative modulator of EGFR signaling. Mouse tracheal epithelial cells (MTEC) from Gprc5a-/- mice exhibited a relative increase in EGFR and downstream STAT3 signaling, whereas GPRC5A expression inhibited EGFR and STAT3 signaling. GPRC5A physically interacted with EGFR through its transmembrane domain, which was required for its EGFR inhibitory activity. Gprc5a-/- MTEC were much more susceptible to EGFR inhibitors than wild-type MTEC, suggesting their dependence on EGFR signaling for proliferation and survival. Dysregulated EGFR and STAT3 were identified in the normal epithelia of small and terminal bronchioles as well as tumors of Gprc5a-/- mouse lungs. Moreover, in these lungs EGFR inhibitor treatment inhibited EGFR and STAT3 activation along with cell proliferation. Finally, overexpression of ectopic GPRC5A in human non-small cell lung carcinoma cells inhibited both EGF-induced and constitutively activated EGFR signaling. Taken together, our results show how GPRC5A deficiency leads to dysregulated EGFR and STAT3 signaling and lung tumorigenesis. Cancer Res; 75(9); 1801-14.
UR - http://www.scopus.com/inward/record.url?scp=84942916194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942916194&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-2005
DO - 10.1158/0008-5472.CAN-14-2005
M3 - Article
C2 - 25744720
AN - SCOPUS:84942916194
SN - 0008-5472
VL - 75
SP - 1801
EP - 1814
JO - Cancer Research
JF - Cancer Research
IS - 9
ER -